Malarial dipeptidyl aminopeptidases (DPAPs) are cysteine proteases important for parasite development thus making them attractive drug targets. In order to develop inhibitors specific to the parasite enzymes it is necessary to map the determinants of substrate specificity of the parasite enzymes, and its mammalian homologue cathepsin C (CatC). Here, we screened peptide-based libraries of substrates and covalent inhibitors to characterize the differences in specificity between parasite DPAPs and CatC and used this information to develop highly selective DPAP1 and DPAP3 inhibitors. Interestingly, while the primary amino acid specificity of a protease is often used to develop potent inhibitors, we show that equally potent and highly specific inhibitors can be developed based on the sequences of non-optimal peptide substrates.
Introduction
Malaria is a devastating infectious parasitic disease causing nearly half a million deaths every year (World Health Organization 2017) . Malaria is caused by parasites of the Plasmodium genus and is transmitted by Anopheles mosquitoes during a blood meal. Within the mosquito midgut, parasites reproduce sexually, multiply, and travel to the salivary glands from where they are transmitted to the human host. Upon infection, the parasites first establish an asymptomatic infection in the liver, followed by an exponential asexual replication in the blood stream, through multiple rounds of red blood cell (RBC) invasion, intracellular replication and egress from infected RBCs, this erythrocytic cycle is responsible for the symptoms and pathology of this disease. Over the last 15 years the world has seen a very significant drop in malaria incidence, mainly due to the global distribution of insecticide-impregnated bed nets and the use of artemisinin-based combination therapies as the standard of care for uncomplicated malaria (Bhatt et al. 2015) . However, malaria remains a major global health burden with half of the world population at risk and around 200 million clinical cases per year. Unfortunately, mosquitoes are becoming increasingly resistant to insecticides (Ranson & Lissenden 2016 ) and artemisinin resistance is on the rise (Ashley et al. 2014) , thus making the identification of antimalarial targets and the development of drugs with novel mechanism of action extremely urgent (Wells et al. 2015) .
Dipeptidyl aminopeptidases (DPAPs) are papain-fold cysteine proteases that are expressed at all stages of parasite development Young et al. 2005 ) and might therefore be viable drug targets to treat malaria and prevent its transmission. DPAPs recognize the free N-terminus of protein substrates and cleave N-terminal dipeptides (GUTMANN & FRUTON 1948; WIGGANS et al. 1954) . The mammalian homologue cathepsin C (CatC) is the best studied DPAP (Korkmaz et al. 2018) . In most cells, CatC plays a catabolic lysosomal function. However, in immune cells it is responsible for activating various granule serine proteases involved in the immune response and inflammation such as neutrophil elastase, chymase, granzyme A and B, or cathepsin G (McGuire et al. 1993; Kummer et al. 1996; Pham & Ley 1999; Adkison et al. 2002) . Because of its role in activating pro-inflammatory proteases, CatC has been pursued as a potential target for chronic inflammatory diseases (Guay et al. 2009; Lainé et al. 2011; Furber et al. 2014) , and phase I clinical trials with CatC inhibitors have been performed by GSK (GSK2793660) (Miller et al. 2017 ) and Astrazeneca (AZD7986) (Palmér et al. 2018) , thus proving that DPAPs can be targeted with small drug-like molecules.
Three DPAPs are conserved across Plasmodium species but very little is known about their molecular functions. In P. falciparum, the most virulent Plasmodium specie responsible for 90% of malaria mortality, attempts to directly knockout (KO) DPAP1 (Klemba et al. 2004) or DPAP3 (Lehmann et al. 2017 ) have been unsuccessful, suggesting that they are important for parasite replication. Also, in the P. berghei murine model of malaria, KO of DPAP1 or DPAP3 results in a significant decrease in parasite replication (Lin et al. 2015; Capuccini et al. 2016; Schwach et al. 2015) . DPAP1 localizes mainly in the digestive vacuole (Klemba et al. 2004) , an acidic organelle where degradation of haemoglobin takes place. This proteolytic pathway provides a source of amino acids for protein synthesis and liberates space within the RBC for parasites to grow. DPAP1 has been proposed to play an essential role at the bottom of this catabolic pathway (Klemba et al. 2004) , , however, this function has not yet been confirmed genetically. Previously published inhibition studies suggested that DPAP3
was at the top of the proteolytic cascade that controls parasite egress form iRBCs . However, our recent conditional KO studies have disproven this hypothesis and shown that DPAP3 is instead critical for efficient RBC invasion (Lehmann et al. 2017) . Finally, DPAP2 is only expressed in sexual stages and has been shown to be important for gamete egress from iRBCs, thus making it a potential target to block malaria transmission (Suárez-Cortés et al. 2016) , (Tanaka et al. 2013) . Overall, a pan-DPAP inhibitor will target the parasite at different stages of development, thus potentially slowing down the emergence of resistance.
A clear understanding of the determinants of substrate specificity of Plasmodium
DPAPs and CatC will be required in order to develop pan-DPAP inhibitors with minimal off target effects on host CatC, and to design highly specific inhibitors to study the biological function of DPAP1 and DPAP3. A general approach to determine the specificity of proteases upstream of the scissile bond (non-prime pockets) is the use of positional scanning substrate libraries where a fluorophore is conjugated to the C-terminus of a peptide library via an amide bond. Proteolytic cleavage of this bond results in a significant increase in fluorescence intensity allowing accurate measurement of substrate turnover. The most common libraries used for this purpose are positional scanning synthetic combinatorial libraries (PS-SCL) (Thornberry et al. 1997; Rano et al. 1997; Harris et al. 2000) . PS-SCL are composed of multiple sub-libraries designed to determine the specificity of each non-prime binding pocket in a protease. In each sub-library, the amino acid (AA) at a specific position is varied while a stoichiometric mixture of all natural AAs is used in all other positions. PS-SCL thus provide the substrate specificity at each site in the context of all possible combination of AAs at all other positions. Alternatively, the specificity of a given binding pocket can be determined by varying the identity of the AA at that position while fixing the rest of the peptide to residues known to be recognized by the protease of interest. This approach has been used to fingerprint the specificity of amino exopeptidases such as aminopeptidases (Drag et al. 2010; Poreba et al. 2012) or DPAPs (Poreba, Mihelic, Krai, Rajkovic, Krezel, Pawelczak, Klemba, D. Turk, B. Turk, Latajka & Drag 2014b ), which only recognize one or two AAs upstream of the scissile bond, respectively. PS-SCL have also been applied to protease inhibitor libraries by replacing the fluorophore with a reversible or irreversible warhead (Nazif & Bogyo 2001) . Optimum substrates and inhibitors are then designed by combining the best residues in each position. Importantly, the recent incorporation of non-natural AAs into these libraries has significantly increased the chemical space that can be explored to characterize the specificity of proteases and has allowed the design of substrates and inhibitors with enhanced selectivity over compounds that contain only natural amino acids (Greenbaum, Arnold, et al. 2002; Kasperkiewicz et al. 2014; Kasperkiewicz et al. 2017 ).
Structure-activity relationship (SAR) studies with positional scanning substrate and inhibitor libraries have been performed both on DPAP1 and CatC (Poreba, Mihelic, Krai, Rajkovic, Krezel, Pawelczak, Klemba, D. Turk, B. Turk, Latajka & Drag 2014a; Wang et al. 2011; ), but to a much lesser extent on DPAP3(Arastu-Kapur et al.
2008
). Here, we used libraries of peptide-based substrates and inhibitors to determine the specificity of P. falciparum DPAP3 at the P1 and P2 positions. Importantly, the libraries used in this study have been previously screened against DPAP1 and CatC and are therefore ideal to compare the specificities of these three proteases (Poreba, Mihelic, Krai, Rajkovic, Krezel, Pawelczak, Klemba, D. Turk, B. Turk, Latajka & Drag 2014b) . Our studies show that DPAP3 preferentially cleaves after basic and large aromatic residues (P1 position) and that it prefers substrates having N-terminal aliphatic residues (P2 position). We also identified several nonnatural P2 residues that are exclusively recognized by either DPAP1 or DPAP3. By combining the SAR information obtained from these substrate and inhibitor screens we developed specific DPAP1 and DPAP3 inhibitors that remain selective in live parasites. Interestingly, while SAR information obtained from positional scanning substrate libraries is often used to develop potent protease inhibitors (Kasperkiewicz et al. 2017) , we have identified significant differences in specificity between substrates and inhibitors, particularly in the case of DPAP3 and to a lesser extent for CatC and DPAP1. Surprisingly, we also observed significant discrepancies when we compared previously published specificity data about cysteine cathepsins and caspases obtained from PS-SCL of substrates and inhibitors.
Overall, our study shows that while highly potent inhibitors can be designed based on the sequence of optimal substrates, equally potent and specific inhibitors can be developed using sequences of non-optimal substrates. This work also illustrates how positional scanning substrate libraries might not always identify optimal AAs for inhibitor development.
Results

DPAP3 Substrate Specificity.
A positional scanning library of 96 substrates ( Figure 1A ), composed of a P1 sub-library of 39 substrates (P2 fixed to Met) and a P2 sub-library of 57
substrates (P1 fixed to homophenylalanine (hPhe)), was screened at 1 µM against recombinant DPAP3 (DPAP3; Figure 1B -C). The heat map shown in Figure 1B Phg is the only substrate containing a D-AA that is shown in Figure 1 .
All three DPAPs show broad and similar P1 specificity, which is not surprising because in clan CA proteases the P1 residue side chain is solvent exposed. For all DPAPs, a general preference for long basic, aliphatic, and aromatic P1 residues was observed-basic: Lys, Arg, homoarginine (hArg), and nitroarginine (Arg (NO 2 )); aliphatic: Met, norvaline (nVal) and Leu; aromatic: hPhe, (4-benzothiazol-2-yl)homoalanine (hAla (Bht)), 6-benzyloxynorleucine (nLeu(o-Bzl)), glutamic acid benzyl ester (Glu (Bzl)), and homoserine-O-benzyl (hSer (Bzl))-
. Interestingly, DPAP1 differs from CatC and DPAP3 in that it does not accept large hydrophobic groups such as cyclohexylalanine (Cha), 2-naphthalene (2Nal), biphenylalanine Clear differences in specificity were observed between the three DPAPs at the P2 position ( Figure 1B surprised by the lack of activity observed for substrates with aromatic P2 residues, we measured Michaelis Menten parameters for Phe-Arg-ACC, Trp-hPhe-ACC, and Tyr (NO 2 )-hPhe-ACC.
The sequence of the last substrate is based on the structure of SAK1 (Tyr (NO 2 )-hPhe-VS), which is the most potent DPAP3 inhibitor identified so far (see below). Table 1 and Figure 1D report the Michaelis Menten parameters determined for all these substrates (Michaelis Menten curves are shown in Figure S1 ). (Poreba, Mihelic, Krai, Rajkovic, Krezel, Pawelczak, Klemba, D. Turk, B. Turk, Latajka & Drag 2014b) 2 For DPAP1, k cat = 6.2 ± 0.4 s -1 , K m = 84 ± 9 µM and k cat /K m = 74,000 ± 2000 M -1 s -1 ; for CatC, k cat = 490 ± 10 s -1 , K m = 130 ± 10 µM and k cat /K m = 3,600,000 ± 300,000 M -1 s -1 . (Wang et al. 2011) 3 For DPAP1, k cat = 3.5 ± 0.1 s -1 , K m = 21 ± 2 µM and k cat /K m = 170,000 ± 10,000 M -1 s -1 ; for CatC, k cat = 180 ± 10 s -1 , K m = 51 ± 8 µM and k cat /K m =3,600,000 ± 300,000 M -1 s -1 . (Wang et al. 2011) P1 residues have a significant influence in k cat , with nLeu(o-Bzl) and positively charged residues having the highest values. A positive charge on the d position (Arg (NO 2 ) and Arg) is favoured over the e position (Lys and hArg). Elongated aliphatic and hydrophobic residues in P1 decrease K m , especially when aromatic groups are distant from the peptide backbone. This is evident by the decreasing K m values between nVal, Met, hPhe, Bpa, Glu (Bzl), and nLeu(oBzl). This tendency was also observed for CatC and DPAP1, and might suggest the presence of a distal binding pocket ( Figure 1B) , potentially an exosite, since P1 residues are usually solvent exposed in clan CA proteases.
P2 residues have a bigger influence on K m than P1, with Leu and nVal being optimal P2 residues for DPAP3. Beta branched residues are not optimal for DPAP3 as can be observed by an increase in K m between nVal and Val or nLeu and Ile. However, the g-branched AA Leu has the lowest K m . Substrates with aliphatic P2 side chains that extend to the d position (Met and nLeu) result in higher K m values than slightly shorter ones (Leu and nVal) but also higher k cat values. Overall, combining optimal P1 (nLeu(o-Bzl) and Arg) and P2 (nVal and Leu) residues results in improved k cat /K m values (Table 1) .
Interestingly, although substrates with Phg and indanyl-glycine (Igl) in P2, or Bpa in P1, are not the preferred AAs at these positions, these non-natural residues are structurally very different from natural AAs and are turned over quite efficiently by DPAP3 when combined with optimal P1 or P2 residues, respectively, i.e. Leu-Bpa-ACC or Phg-nLeu(o-Bzl)-ACC.
Finally, the optimal substrate for DPAP1, hPro-hPhe-ACC (Poreba, Mihelic, Krai, Rajkovic, Krezel, Pawelczak, Klemba, D. Turk, B. Turk, Latajka & Drag 2014b) , is very poorly turned over by DPAP3 (> 200-fold difference in k cat /K m ). We think that substrates containing these non-natural AAs could be used as specific tools to measure DPAP1 or DPAP3 activity in biological samples, i.e. parasite lysates or live parasites, an application we are currently investigating.
Finally, our studies show that substrates with aromatic P2 residues are poorly cleaved by DPAP3 compared to optimal substrates, i.e. 100 to 1000-fold lower k cat /K m . This is surprising since vinyl sulfone inhibitors containing aromatic P2 residues such as Tyr (NO 2 ) or Trp, are potent and selective DPAP3 inhibitors Lehmann et al. 2017 ).
Because these two AA side chains have fluorogenic properties, we investigated whether the low turnover rate measured for Tyr (NO 2 )-hPhe-ACC and Trp-hPhe-ACC might be due to quenching effects. The emission of free ACC (0, 1, or 5 µM) in assay buffer was measured in the presence of 0-100 µM of these substrates ( Figure S2A -B) . No significant decrease the ACC emission signal was observed even when substrates were present in 100-fold excess, thus indicating that the low turnover rates measured for these substrates are not due to quenching effects.
As an alternative method to confirm that Tyr (NO 2 )-hPhe-ACC and Trp-hPhe-ACC bind relatively poorly to DPAP3, we performed substrate competition assays using the (PR) 2 Rho substrate (l ex = 492 nm, l em = 523 nm), which emits at much higher wavelengths than ACC (l ex = 355 nm, l ex = 460 nm), and thus allowing us to simultaneously measure the turnover of (PR) 2 Rho and ACC substrates without quenching interference. (PR) 2 Rho was initially designed as a DPAP1 specific substrate to directly measure the activity of this protease in crude parasite extracts ), but it is also cleaved by DPAP3 with a K m,app of 40 µM ( Figure S2C ). This substrate is cleaved twice by DPAPs, releasing two Pro-Arg dipeptides and the rhodamine 110 fluorophore. In this assay, we simultaneously measured inhibition of (PR) 2 Rho turnover by ACC substrates (IC 50 values) as well as the apparent K m values of these ACC substrates in the presence of 40 µM (PR) 2 Rho (K m,app values). As shown in Figure S2D , the IC 50 and K m,app values obtained are within experimental error and, as expected, slightly higher than the K m values reported in Table 1 due to the substrate competition effect. Overall, the lack of quenching effect between Trp or Tyr (NO 2 ) and ACC, and the good agreement between IC 50 and K m,app measured under substrate competition conditions indicate that the Michaelis Menten parameters reported in Table 1 are accurate and that substrates containing aromatic P2 AAs are indeed relatively poor DPAP3 substrates compared to those containing optimal aliphatic P2 residues. These results raise the question of why vinyl sulfone inhibitors with aromatic P2 residues are among the most potent DPAP3 inhibitors identified so far. To better understand this discrepancy, we measured the kinetics of inactivation of DPAP3 by the previously published vinyl sulfone inhibitor library ).
DPAP3 Inhibitor Specificity.
Time-and concentration-dependent inactivation of DPAP3 by the P2 library of vinyl sulfone inhibitors (P1 fixed to hPhe) was measured using a continuous assay at 2.2 µM of Met-nLeu(o-Bzl)-ACC (0.25 x K m ). For most compounds, the mechanism of inhibition was consistent with a two-step irreversible inhibition model (Eq. 1, Figure 2A ).
Eq. 1
K i is the inhibition equilibrium constant, and k inact the rate of covalent modification of the catalytic Cys.
For a few inhibitors only k inact /K i values could be obtained, i.e. no saturation was achieved in the k obs vs.
[I] graph ( Figure 2B ). The inhibition constants are reported in Figure 2C and Table 2 , and the curve fits shown in Figure S3 . Only one inhibitor, the one with an aminomethyl-benzyl (Amb) group in P2, was not able to inhibit DPAP3 in a time-dependent manner under our assay conditions ( Figure 2D ). This is probably due to the fact that this extended and rigid P2 AA ( Figure 2E ) might prevent proper positioning of the vinyl sulfone group into the active site of DPAP3 to allow covalent modification of the catalytic Cys. For this compound, a K i value for reversible inhibition was measured. 
E + I ⇄ E: I → ( − *
Gly 4.2 ± 0.3 3,300 ± 750 1.30 ± 0.25 3.0 ± 0.2 3,300 ± 750 0.9 ± 0.1 3.0 ± 0.2 70 ± 9 43 ± 4 Ala 2.4 ± 0.1 88 ± 13 27 ± 3 3.03 ± 0.09 90 ± 7 34 ± 2 3.00 ± 0.06 9.7 ± 0.4 310 ± 8 Acpc 3.2 ± 0.1 47,000 ± 3,000 0.0677 ± 0.0001 6.2 ± 0.3 49,000 ± 4,000 0.127 ± 0.006 1.03 ± 0.06 3,200 ± 700 0.33 ± 0.06 hAla 2.2 ± 0.3 13.5 ± 6 166 ± 50 5.2 ± 0.7 19 ± 4 267 ± 26 2.9 ± 0.2 5.9 ± 0.9 500 ± 50 Aib N.S. N.S. 0.0363 ± 0.0006 8.9 ± 0.5 18,000 ± 2,000 0.49 ± 0.03 1.20 ± 0.07 2,100 ± 300 0.57 ± 0.06 Val 3.2 ± 0.2 5.7 ± 1.1 554 ± 84 3.6 ± 0.2 2.6 ± 0.4 1,380 ± 140 2.9 ± 0.1 14 ± 2 200 ± 15 Ile 3.4 ± 0.4 23 ± 9 148 ± 45 3.2 ± 0.1 92 ± 8 34 ± 3 3.7 ± 0.8 1,300 ± 400 2.9 ± 0.3 nLeu 3.7 ± 0.2 31 ± 3 120 ± 7.5 4.4 ± 0.3 14 ± 2 305 ± 24 2.40 ± 0.05 7.0 ± 0.5 340 ± 20 Cba 2.5 ± 0.1 140 ± 25 17 ± 2.5 5.4 ± 0.4 13,000 ± 2,000 0.41 ± 0.03 1.29 ± 0.03 2,400 ± 140 0.53 ± 0.02 Thr 2.0 ± 0.1 36 ± 8 55 ± 10 4.4 ± 0.2 112 ± 10 39 ± 2 2.38 ± 0.03 65 ± 3 36 ± 1 Asn 7.4 ± 0.8 2,100 ± 1,000 3.5 ± 1.4 9.9 ± 0.5 10,500 ± 750 0.95 ± 0.02 2.40 ± 0.07 260 ± 30 9.2 ± 0.7 Gln 2.9 ± 0.2 80 ± 20 35 ± 8 4.7 ± 0.2 50 ± 3 93 ± 3 2.3 ± 0.1 15 ± 3 160 ± 25 Asp 2.9 ± 0.2 1,900 ± 400 1.5 ± 0. Overall, changes in P2 do not have a big influence in k inact with the exceptions of Asn, Phe(Me), and Tyr (NO 2 ), which significantly increase k inact . Intriguingly, substrates containing the latter two P2 residues were the only substrates with a P2 aromatic residue that could be cleaved by DPAP3 with k cat /K m > 2,000 M -1 s -1 ( Figure 3A , there is not a clear correlation between k cat /K m and k inact /K i for DPAP3
as a function of the P2 residue, however, P2 residues that make optimal substrates also make good inhibitors (Val, nVal, nLeu) .
Correlation between substrate turnover and inhibition for DPAP1 and CatC. (Table S1 and Figure S4 ), and k inact and K i values for DPAP1 and CatC for the P2 vinyl sulfone library (Table 2 and Figure S3 ). As shown in Figure 3B , we observed a good correlation between substrate turnover and k inact /K i for DPAP1, but for CatC we observed some discrepancies ( Figure 3C ), albeit not as pronounced as in the case of DPAP3. For example, the CatC k cat /K m for Phe(Me)-hPhe-ACC is 30-fold higher than for Phg-hPhe-ACC while the k inact /K i for Phe(Me)-hPhe-VS is 13-fold lower than for Phg-hPhe-VS, thus resulting in a 400-fold discrepancy in the changes in k cat /K m and k inact /K i values between these two P2 residues. . k cat /K m,app were calculated similarly for DPAP3 and CatC for P2 substrates whose activity was too low to obtain accurate Michaelis Menten parameters (i.e., substrates not present in Tables 1  and S2 ). Filled circles correspond to compounds belonging to the vinyl sulfone library (compounds in Table  2 ), and empty circles to inhibitors having a phenyl group in P1' ( Table 3 ). The P2 residue is labelled next to each data point. Pearson correlation coefficients (r) are shown for each protease. (D-F) Comparison of changes in substrate turnover relative to inhibitors potency for any pair of P2 residues. The log value of DACT/DINH (Eq. 2) calculated for DPAP3 (D), DPAP1 (E) and CatC (F) are shown has a heat map with values above and below zero in red and blue, respectively. Each pairwise value showing more than a 100-fold discrepancy between activity and inhibition (DACT/DINH > 100 or < 0.01) is highlighted in bold.
A systematic way to visualize discrepancies between substrate turnover and inhibition is to compare the fold different in k cat /K m with that in k inact /K i for any two P2 residues (Eq. 2). Eq. 2
We performed these pairwise calculations for each of the DPAPs studied here and have presented the results as heat maps in Figure 3D -F. We observed significant and numerous discrepancies between substrates and inhibitors for DPAP3 (30 % of pairwise DACT/DINH > 100 or < 0.01), almost no discrepancies for DPAP1 (only 1% DACT/DINH > 10 2 or < 10 -2 ), and only a few for CatC (4% of DACT/DINH > 100 or < 0.01). Overall, this study indicates that the level of correlation between k cat /K m and k inact /K i is protease dependent.
Development of DPAP1 and DPAP3-selective inhibitors.
We next synthesized several inhibitors to determine whether the optimal nLeu(o-Bzl) P1 residue identified from the substrate screen could be used to increase the potency and specificity of inhibitors towards DPAP1 or DPAP3. We selected P2 AAs that were predicted to provide specificity towards DPAP1 (Pro and hPro) or DPAP3 (aromatic residues: Tyr (NO 2 ), Trp, Igl and 2Nal) based on our substrate and inhibitor screening results. We also included in our analysis the previously synthesized compound JCP410 (nVal-hPhe-VS) ), since nVal is one of the best P2 residues identified from the substrate screen. We determined the inhibition constants of these compounds for DPAP1, DPAP3, and CatC (Table 3 and Figures 2 and S3 ).
The major structural difference between these compounds and the inhibitor library is that they have a phenyl group in P' instead of a long aliphatic linker (Figure 2A ). This change usually increases the potency of compounds except in the context of a P2 Trp for DPAP3 or P2 Tyr (NO 2 )/2Nal for CatC (Tables 2 and 3 ). These exceptions indicate some level of interdependence between the prime and non-prime sites of DPAPs. and CatC, respectively) making it a highly potent but non-selective pan-DPAP inhibitor Pro-hPhe-VS (SAK2) is 100-fold more selective towards DPAP1 than DPAP3, but only shows a 10-fold selectivity for DPAP1 compared to CatC. While replacing the P2 Pro of SAK2 with hPro increases the potency of the inhibitors towards DPAP1, this also results in some loss of specificity (Table 3 ). Overall, we were able to increase the potency of SAK2 (Pro-hPhe-ACC) towards DPAP1 by 7-fold by using the optimal P1 (nLeu(o-Bzl)) and P2 (hPro) Testing inhibitors specificity in live parasites. We then tested the potency and selectivity of our DPAP1 and DPAP3 specific inhibitors in live parasites using the FY01 activity-based probe (ABP) in a competition labelling assay. ABPs are small molecule reporters of activity that use the catalytic mechanism of the targeted enzyme to covalently modify its active site. A reporter tag, usually a fluorophore or a biotin, allows visualization and quantification of the labelled enzyme in a gel-based assay (Sanman & Bogyo 2014) . FY01 is a cell-permeable fluorescent ABP that was initially developed for CatC (Yuan et al. 2006 ) but it also labels Plasmodium DPAPs and the falcipains in live parasites ).
The falcipains (FPs) are clan CA Cys proteases involved in haemoglobin degradation (FP2, FP2' an FP3) (Sijwali et al. 2006 ) and possibly RBC invasion (FP1) (Sijwali et al. 2004; Greenbaum, Baruch, et al. 2002) . Binding of inhibitors into the active site of any of these Cys proteases prevents probe labelling resulting in the disappearance of a fluorescent band a SDS-PAGE gel.
Live parasites were treated with different concentrations of inhibitor for 30 min, and the residual level of DPAPs and FPs activities labelled with FY01 ( Figure S5 ) and quantified by densitometry. Dose response curves are shown in Figure 4 and IC 50 values reported in Table 4 .
Inhibitors with a P2 Pro or hPro are equally potent and inhibit DPAP1 at mid nanomolar concentrations. However, the P2 Pro makes the inhibitor more selective by blocking inhibition of the FPs. Compounds with a P2 Trp or Tyr (NO 2 ) are highly specific for DPAP3 in intact parasites. Surprisingly, Trp-hPG-VS is by far the most potent DPAP3 inhibitor in intact parasites (IC 50 = 1.4 nM) despite being 5 to 100-fold less potent than Trp-nLeu(o-Bzl)-VS or Trp-hPhe-VS against DPAP3 (see k inact /K i values in Table 3 ). This suggests that either this compound is metabolically more stable and/or that decreasing the hydrophobicity of the P1 residue enhances the cell permeability of the compound. Indeed, compounds need to cross four membranes to reach DPAP3: the RBC, parasitophorous vacuole, and parasite plasma membranes, plus the membrane of the apical organelle where DPAP3 resides (Lehmann et al. 2017 ). (The parasitophorous vacuole is a membrane bound structure within which the parasite growth and multiply isolated from the RBC cytosol.) It is also likely that the apparent increased potency of Trp-hPG-VS in live parasites might be due to its accumulation into the DPAP3 acidic organelle via protonation of its free amine. However, we predict that this lysosomotropic effect likely occurs for all DPAP inhibitors presented here. 3,300 ± 1,000 Pro-hPhe-VS > 10,000 275 ± 25 ~ 10,000 > 10,000 hPro-nLeu(o-Bzl)-VS 900 ± 100 62 ± 7 300 ± 100 1,900 ± 500 Tyr (NO 2 )-hPhe-VS 190 ± 20 > 10,000 > 10,000 > 10,000 Tyr (NO 2 )-nLeu(o-Bzl)-VS 730 ± 170 > 10,000 > 10,000 > 10,000 L-Trp-hPG-VS 1.4 ± 0.4 > 10,000 > 10,000 > 10,000 L-Trp-hPhe-VS 130 ± 60 > 10,000 > 10,000 > 10,000 L-Trp-nLeu(o-Bzl)-VS 760 ± 150 ~ 10,000 ~ 10,000 ~ 10,000 D-Trp-hPhe-VS 6,800 ± 1,600 > 10,000 > 10,000 > 10,000 D-Trp-nLeu(o-Bzl)-VS 2,700 ± 1,600 > 10,000 > 10,000 > 10,000
Correlation between PS-SCL of substrates and inhibitors for other Cys proteases. To determine whether the discrepancy observed between substrate and inhibitor specificities for DPAP3 ( Figure 3 ) is a phenomenon observed in other proteases, we look at previously published literature about two of the most commonly studies families of Cys proteases, i.e. caspases and cathepsins. Several studies on caspases (Berger, Sexton, et al. 2006; Poreba et al. 2018 ) and cathepsins (Choe et al. 2006 ) have shown that inhibitors designed based on the structure of specific substrates do not retain their selectivity. Also, the sequence of an optimal substrate or inhibitor might render the equivalent inhibitor or substrate completely inactive 51, (Choe et al. 2006) . We therefore compared previously published specificity data obtained from PS-SCL libraries of ACC substrates and covalent inhibitors for these two protease families ( Figure 5 ).
To simplify our analysis, we only compared data obtained from natural amino acids. For
Cys cathepsins (CatB, CatF, CatK, CatL, CatS, and CatV), we compared the substrate specificity data obtained from the Craik lab (Choe et al. 2006 ) with the inhibitor specificity data obtained from the Bogyo lab using an epoxide library (Greenbaum, Arnold, et al. 2002) ( Figure 5A-B) . For caspases, we compared the specificity obtained for caspases 3, 8 and 9
(Casp3, Casp8 and Casp9, respectively) using a library of acyloxymethyl ketone inhibitors from the Bogyo lab (Berger, Witte, et al. 2006) , with the substrate specificity results from the Drag lab (Poreba, Kasperkiewicz, et al. 2014) (Figure 5C-D) . For each protease, we normalized the level of activity and inhibition to that of the best natural amino acid at each P2-P4 position. As shown in Figure 5 , there is very poor correlation between the levels of activity and inhibition.
Indeed, for most proteases and P2-P4 positions, the Pearson coefficients are below 0.7. Similar to what we observed for DPAPs (Figure 3) , the peptide sequence of inhibitors that is equivalent to that of optimal substrates generally yields very potent inhibitors. This is true for most proteases and for each position (with the exception of P2 in Casp9). However, for all proteases, 90-100 % inhibition was achieved with peptide sequences that were poorly cleaved as substrates (< 10 % activity). Also, at each P2-P4 position we could observe good inhibition with sequences belonging to poor substrates. Interestingly, for most proteases only a few peptide sequences showed good turnover rates but poor inhibition, with the exception of Casp8, and the P3 position for CatF. There are also a few striking individual residues, such as P2 His for caspases 8 and 9, or P2 Thr for Casp3 and P2 Val for CatS, that show good activity but no inhibition. Finally, we would also like to draw attention to the fact that the P2 and P4 positions are particularly important for modulating the potency of inhibitors against Casp9 and Casp3, respectively. However, these positions have little effect on substrate turnover. A possible explanation about the difference in specificity at the P4 position for caspases is that the P4 capping group is different between the substrate (acetyl group) and inhibitor (2-(4-hydroxy-3-nitrophenyl)-acetyl group) PS-CSLs, and might therefore strongly influence how the side chain of P4 residues bind into the S4 pocket. Indeed, using different capping group in PS-CSL of substrates has been shown to result in different amino acid preference in the S4 pocket of the Zika virus NS2B-NS3 protease (Rut et al. 2017; Gruba et al. 2016) . Also, the difference in specificity might be due to cooperativity between the prime and non-prime sites (especially at the P2 position). In this case the choice of electrophile used might change the amino acid preference. (A and C) Structure of the PS-SCL of ACC substrates and inhibitors used to determine the specificity of cathepsins and caspases. For the cathepsins, substrates were screened at 250 µM, and the inhibitors at 10 µM using an ABP competition assay. For caspases, substrates were screened at 50 µM and inhibitors at 50-500 nM. (B and D) Correlation between substrate turnover and inhibition. For each protease and P2-P4 position, the maximum level of activity and inhibition at each AA position was normalized to 100 %. Pearson correlation coefficients (r) are shown next to the legend of each graph for each position. The lower r value was obtained by combining all the P2-P4 data points for each protease. Residues showing maximum activity or inhibition are labelled at each position along with specific AAs that illustrate particularly bad correlation between the levels of activity and inhibition.
Discussion
This study provides the first characterization of the specificity of DPAP3, a cysteine protease important for efficient invasion of RBCs by the malaria parasite (Lehmann et al. 2017 ). DPAP3
is a highly efficient proteolytic enzyme showing similar k cat and k cat /K m values than either DPAP1 or CatC when optimal substrates are used (Table 1 ). In general, DPAP3 has a narrower substrate specificity than either DPAP1 or CatC, and it preferentially cleaves substrates with aliphatic residues at the N-terminus. Our study also shows similar P1 substrate specificity across all DPAPs, i.e. a strong preference for basic or long aromatic residues. DPAP3 was the only DPAP able to cleave some substrates with aromatic P2 residues (Tyr, Phe(Me), Phg), albeit with relatively low turnover rates. Surprisingly, vinyl sulfone inhibitors with aromatic residues are as potent as compounds with optimal P2 residues identified from the substrate screen, but in addition, these compounds are highly specificity for DPAP3 compared to DPAP1, CatC, or other malarial cysteine proteases (FPs). The previously described DPAP1
inhibitor SAK2 (Pro-hPhe-VS) shows the greatest specificity for DPAP1 in live parasites.
Incorporation of optimal P1 (nLeu(o-Bzl)) and P2 (hPro) residues identified from the substrate screens improves the potency of DPAP1 inhibitors both in vitro and in live parasites, but also results in some loss in specificity (Table 3 and Figure 4 ).
Despite being highly potent and specific DPAP1 and DPAP3 inhibitors, these compounds only show antiparasitic activity at mid to high micromolar concentrations Arastu-Kapur et al. 2008; Lehmann et al. 2017) , probably due to metabolic stability issues. Indeed, we have previously shown that this is the case for Pro-hPhe-VS, which
is not able to sustain target inhibition in live parasites . A possible cause for this instability is the presence of multiple aminopeptidases in the malaria parasite that might cleave the amide bond of these compounds (Deu 2017) , thus preventing them to bind into the DPAPs active sites. Nonetheless, this study provides a very strong SAR foundation to develop potent non-peptidic inhibitors able to sustain DPAPs inhibition. From a drug development point of view, our SAR studies indicate that inhibitors with short aliphatic P2 residues strongly inhibit both DPAPs ( Figure 3E ), indicating that potent pan-DPAP inhibitors can easily be developed. Unfortunately, we did not identify any clear P1 or P2 residue that would discriminate malarial DPAPs from host CatC. Therefore, further studies are required to determine whether differences in specificity in the prime binding pockets can be exploited to develop parasite specific inhibitors.
It is however important to point out that given the short-term treatment requirement for antimalarial therapy (single dose or less than 3 doses in 3 days), we think it is unlikely that inhibition of CatC would lead to adverse side effects. Firstly, highly specific DPAP inhibitors might not be necessary given that a high level (> 95 %) of sustained CatC inhibition is required to see a decrease in the activity of serine proteases activated by CatC (Methot et al. 2008 ).
Secondly, activation of granule serine proteases by cathepsin C takes place during cell differentiation in the bone marrow, and a decrease in the level of serine proteases activity in circulating immune cells is only achieved after more than 2 weeks of daily treatment with CatC inhibitors (Palmér et al. 2018) . And thirdly, no signs of toxicity were observed in phase I clinical trials when volunteers were treated daily for more than 3 weeks with CatC inhibitors, albeit some on-target side effects such as plantar and palmar epithelial desquamation were observed in some instances (Miller et al. 2017; Palmér et al. 2018) . However, these side effects were not observed in volunteers that received a single dose of CatC inhibitor, nor within the first week of daily treatments.
Positional scanning substrate libraries have been used over the last 20 years (Thornberry et al. 1997; Rano et al. 1997; Harris et al. 2000) to determine the specificity of proteases and guide the synthesis of inhibitors. Here we have shown that vinyl sulfone inhibitors containing P1 and P2 residues corresponding to optimal DPAP1 or DPAP3 substrates result in extremely potent inhibitors. However, our studies clearly identified differences in specificity between substrates and inhibitors, especially for DPAP3, but also for CatC and more generally in caspases and cysteine cathepsins (Figures 3 and 5) . A reason why this phenomenon might not have been more broadly reported in the literature is because, in general, either substrate or inhibitor libraries are used to determine the specificity of a protease, but not both. Also, inhibitors are not usually designed based on the structure of non-optimal substrates. That said, there are multiple reasons that can account for this discrepancy in specificity between substrates and inhibitors:
First, although the substrate and inhibitor libraries used in this study have equivalent P1
and P2 residues, the structural features that bind into the S' pockets are quite different.
Therefore, if the specificity of a protease shows interdependence between its prime and nonprime binding pockets, it might explain the difference in specificity. This is likely the case for DPAPs since we observed a 50-fold increase in k cat between the Phe-Arg-ACC and Phe-ArgbNA substrates, which only differ in the structure of the fluorophore that binds in the S1' pocket (Table 1) . Also, while we observed very good correlation between k cat /K m and k inact /K i of DPAP1 for the P2 substrate and VS library (compounds in Table 2 ), in the context of a phenyl group in P1' (inhibitors in Table 3 ), we observed clear discrepancies between substrates and inhibitors ( Figure 3B ).
Second, the position of the electrophilic warhead within the active site might differ from that of the scissile bond in a substrate, especially in terms of distance and orientation relative to the catalytic Cys. This positioning might be differently affected by changes in the P1 and P2
residues of substrates and inhibitors. Indeed, a recent study on caspases has shown that acyloxymethyl ketone covalent inhibitors might act through a reversible mechanism even if they are designed based on the sequence of optimal substrates (Poreba et al. 2018) . Also, ABPs designed to profiled deubiquitinating proteases by conjugating an electrophile to the C-terminal of ubiquitin have been shown to label different subset of enzymes depending on the warhead used (Borodovsky et al. 2002) . And fourth, the reaction mechanism between covalent inhibition and substrate turnover are quite different making k cat , K m , and k cat /K m not directly comparable with k inact , K i , and contribution of both, depending on the nature of the P1 residue (Schneck et al. 2008; Rubach et al. 2012) .
Although several studies have compared the potency of inhibitors to the turnover of equivalent substrates for selected peptide sequences, to the best of our knowledge this is the first study that systematically compares the potency of a peptide-based covalent inhibitor library to the turnover efficiency of an equivalent substrate library. We think that the discrepancies observed here between k cat /K m and k inact /K i are likely to be present in other proteases, as shown for cysteine cathepsins and caspases, but the level of discrepancy will be dependent on the protease studied as well as on the type of substrate and covalent inhibitor that are being compared especially if a there is a high level of cooperativity between the prime and non-prime binding pockets.
Overall, our detailed study on DPAPs specificity and our analysis of specificity results obtained from PS-SCL clearly indicate that there are very significant differences in specificity between substrates and covalent inhibitors. Although it is now well established that highly potent inhibitors can be developed based on the structure of optimal substrates, this might sometimes result in some loss of specificity. This study clearly demonstrates that optimal inhibitors with improved specificity can be developed based on the structure of relatively poor substrates. Therefore, we strongly recommend using PS-SCL libraries of inhibitors rather than substrates if the goal is to design specific inhibitors and ABPs, and use PS-SCL substrate libraries to determine the substrate specificity of proteases and to develop highly selective substrates as high throughput dynamic tools to measure protease activity in complex biological samples. described. The syntheses of additional substrates used in this study are described in the supplementary methods and were synthesized following previously published methods (Poreba, Mihelic, Krai, Rajkovic, Krezel, Pawelczak, Klemba, D. Turk, B. Turk, Latajka & Drag 2014b) , (Poreba, Szalek, et al. 2014) . The syntheses of the vinyl sulfone inhibitor library, SAK2, SAK1, L-WSAK and D-WSAK were also previously described (Lehmann et al. 2017) , (ArastuKapur et al. 2008) . The additional DPAP inhibitors used in this study were synthesized following similar methods (Yang et al. 2012) . The synthesis and characterization of these inhibitors and their synthetic intermediates are described in detail in the supplementary methods. The Phe-Arg-bNA and Gly-Arg-AMC substrates were purchased from Sigma.
Materials and Methods
Reagents
Recombinant DPAP3 was expressed in insect cells using the bacculovirus system as recently described (Lehmann et al. 2017) . Bovine CatC was purified to homogeneity from spleen by modification of a method described previously (Anon 2018) , (Horn et al. 2002) .
Recombinant DPAP3 active site titration. Recombinant DPAP3 was expressed in SF9 insect cells and purified from the culture supernatant by sequential ion exchange, Ni-NTA, and size exclusion chromatography as previously described (Lehmann et al. 2017) . To accurately determine the concentration of active DPAP3 in our enzyme stocks we used the FY01 ABP.
Because ABPs only react with the active form of an enzyme and covalently modify its active site, in this case the catalytic Cys, they can be used to perform accurate active site titrations.
Our stock of DPAP3 was diluted 20-fold in assay buffer (100 mM sodium acetate, 100 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, 0.1 % CHAPS, and 5 mM DTT at pH 6), pretreated for 30 min with DMSO or 1 µM SAK1 (Tyr (NO 2 )-hPhe-VS), and DPAP3 labelled with 1 µM FY01 for 1 h at RT. These samples were run on a SDS-PAGE gel along with a serial dilution of free probe (1.5-100 nM). In-gel fluorescence was measured using a Bio-Rad PharosFX flat-bed scanner and the intensity of the fluorescent bands quantified using ImageJ.
The fluorescent signal from the free probe was used as a calibration curve and compared to the difference in signal between the DMSO and SAK1 treated DPAP3 ( Figure S6 ). Using this method, we determined that our DPAP3 stock contained 840 nM of active protease.
Substrate turnover assay. The substrate library was screened in triplicate at 1 µM substrate and 1 nM DPAP3 in assay buffer. Substrate turnover was measured over 30 min at RT using a SpectroMax M5e plate reader: l ex = 355 nm, l em = 460 nm, emission filter 455 nm, for ACC or AMC (7-amino-4-methylcoumarin) substrates; l ex = 315 nm, l em = 355 nm, emission filter 420 nm, for Phe-Arg-bNA); and l ex = 492 nm, l em = 523 nm, emission filter 520 nm for Eq. 6
